Back to companies

Samsung Biologics Co Ltd: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $125 per month (billed Annually)
Signup to View Free Sample

Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities include process development and formulation, contract manufacturing, and project management. Samsung Biologics cell culture development process includes upstream, downstream and analytical technology. Samsung Biologics’ provides manufacturing and quality assurance for clinical and commercial products. In addition, the company also offers infrastructure for partnership with other organizations to develop, refine, and distribute the bio-pharmaceutical products. Samsung Biologics also offers biosafety testing and analytical testing services. It owns manufacturing facilities for cell culture development, purification, quality control, MSAT laboratory. Samsung Biologics is headquartered in Incheon, South Korea.

Headquarters South Korea

Address 300, Songdo Bio-Daero, Yeonsu-Gu, Incheon, 21987


Telephone 82 32 4553114

No of Employees 2,587

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange 207940 ()

Revenue (2021) $1.4B 34.6% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX 63.3% (2021 vs 2020)

Market Cap* $45.5B

Net Profit Margin (2021) XXX 21.3% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

30+

Clinical Trials

Determine Samsung Biologics Co Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

20+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Samsung Biologics Co Ltd’s relevant decision makers and contact details.

18+

Catalyst Calendar

Proactively evaluate Samsung Biologics Co Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

7

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

7

Pipeline Drugs

Identify which of Samsung Biologics Co Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

6

Marketed Drugs

Understand Samsung Biologics Co Ltd’s commercialized product portfolio to stay one step ahead of the market.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Services
Services
Process Development:
Upstream Process Development
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Acquisitions/Mergers/Takeovers In April, the company acquired Biogen’s stake in the Samsung Bioepis joint venture for US$2.3 billion.
2022 Financing Agreements In April, the company along with a biotech division announced to raise US$2.6 billion in a rights offering for existing shareholders.
2022 Plans/Strategy In March, the company announced its plans to purchase a land site to construct its fifth and sixth plants in Songdo, Incheon.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Samsung Biologics Co Ltd Celltrion Healthcare Co Ltd ToolGen Inc Ensol Biosciences Inc Biterials Co Ltd
Headquarters South Korea South Korea South Korea South Korea South Korea
City Incheon Incheon Seoul Daejeon Yongsan-gu
State/Province - - - - Seoul
No. of Employees 2,587 - 71 45 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Net Income Growth

Image for loader
Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Kim Tae-han Chairman Executive Board 2011 64
John Rim Chief Executive Officer; Director; President Executive Board 2020 60
Dongjoong Kim Director; Chief Financial Officer; Managing Director; Senior Vice President Executive Board 2014 56
Sam Machour Senior Vice President Senior Management 2019 58
Yang Eunyoung Vice President Senior Management 2018 47
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer